Tests deep magnetic brain stimulation for bipolar depression
Tests deep transcranial magnetic stimulation as add-on treatment in adults with bipolar depression.
Plain-language title generated from the registry record
Registry title: Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression
Key facts
- Where
- Tianjin, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06524505, who can take part
Where in China
- Tianjin Anding HospitalTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tianjin Anding Hospital
- Trial code
- NCT06524505
- Record updated
- 27 February 2026
- Original description
The aim of this study is to evaluate the feasibility and efficacy of deep transcranial magnetic stimulation (dTMS) as an add-on treatment for bipolar depression. Meanwhile, we aim to evaluate the effect of dTMS on cognitive function of bipolar depressive patients. We hypothesize dTMS would improve depressive symptoms and cognitive function in bipolar disorder.Read full original descriptionShow less
Efficacy, Tolerability, and Cognitive Effects of Deep Transcranial Magnetic Stimulation for Bipolar Depression: a Double-blind, Randomized Controlled Trial
The aim of this study is to evaluate the feasibility and efficacy of deep transcranial magnetic stimulation (dTMS) as an add-on treatment for bipolar depression. Meanwhile, we aim to evaluate the effect of dTMS on cognitive function of bipolar depressive patients. We hypothesize dTMS would improve depressive symptoms and cognitive function in bipolar disorder.
Inclusion: Confirmed diagnosis of bipolar depression; age between 18 and 65 years; a 17-item Hamilton Depression Rating Scale (HDRS-17) score >= 17,; a stable pharmacological regimen maintained for at least 4 weeks prior to the beginning of the treatment phase ; for participants who had previously received antidepressant therapy, a minimum 4-week washout period followed by re-evaluation.
Exclusion: receipt of electroconvulsive therapy, rTMS, transcranial direct current stimulation, transcranial alternating current stimulation, or other neurostimulation treatments within the previous 3 months; a lifetime history of other psychiatric disorders, neurological diseases, or severe brain injury; contraindications to magnetic stimulation, including epilepsy, cardiovascular disorders, or metallic implants in the head; the presence of hypomanic/manic symptoms at baseline or a score greater than 12 on the Young Mania Rating Scale (YMRS); pregnancy or lactation.